Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven S Good

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Journal of Clinical Pharmacology|June 19, 2008
Estimation of human drug clearance using multiexponential techniquesKosalaram Goteti, Patrick J Brassil, Steven S Good, et al.
Plos One|January 9, 2020
Preclinical evaluation of AT-527, a novel guanosine nucleotide prodrug with potent, pan-genotypic activity against hepatitis C virusSteven S Good, Adel Moussa, Xiao-Jian Zhou, et al.
Plos Neglected Tropical Diseases|January 24, 2022
AT-752, a double prodrug of a guanosine nucleotide analog, inhibits yellow fever virus in a hamster modelKai Lin, Steven S Good, Justin G Julander, et al.
Antiviral Research|March 7, 2025
Bemnifosbuvir and ruzasvir in combination exhibit potent synergistic antiviral activity in vitro while maintaining a favorable nonclinical safety profile in vivoSteven S Good, Shouqi Luo, Kai Lin, et al.
Expert Opinion on Investigational Drugs|January 24, 2024
Bemnifosbuvir (BEM, AT-527), a novel nucleotide analogue inhibitor of the hepatitis C virus NS5B polymeraseXiao-Jian Zhou, Steven S Good, Keith Pietropaolo, et al.
Antimicrobial Agents and Chemotherapy|August 23, 2021
Evaluation of AT-752, a Double Prodrug of a Guanosine Nucleotide Analog with <i>In Vitro</i> and <i>In Vivo</i> Activity against Dengue and Other FlavivirusesSteven S Good, Ashleigh Shannon, Kai Lin, et al.
Antimicrobial Agents and Chemotherapy|July 18, 2002
Preclinical and toxicology studies of 1263W94, a potent and selective inhibitor of human cytomegalovirus replicationGeorge W Koszalka, Nelson W Johnson, Steven S Good, et al.
Antimicrobial Agents and Chemotherapy|February 9, 2021
AT-527, a Double Prodrug of a Guanosine Nucleotide Analog, Is a Potent Inhibitor of SARS-CoV-2 <i>In Vitro</i> and a Promising Oral Antiviral for Treatment of COVID-19Steven S Good, Jonna Westover, Kie Hoon Jung, et al.
Antimicrobial Agents and Chemotherapy|October 2, 2019
Safety, pharmacokinetics and antiviral activity of AT-527, a novel purine nucleotide prodrug, in HCV-infected subjects with and without cirrhosisElina Berliba, Maxim Bogus, Frédéric Vanhoutte, et al.
European Journal of Drug Metabolism and Pharmacokinetics|April 23, 2015
Pharmacokinetics of IDX184, a liver-targeted oral prodrug of 2'-methylguanosine-5'-monophosphate, in the monkey and formulation optimization for human exposureXin-Ru Pan-Zhou, Benjamin A Mayes, Hassan Rashidzadeh, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Journal of Clinical Pharmacology|June 19, 2008
Estimation of human drug clearance using multiexponential techniquesKosalaram Goteti, Patrick J Brassil, Steven S Good, et al.
Plos One|January 9, 2020
Preclinical evaluation of AT-527, a novel guanosine nucleotide prodrug with potent, pan-genotypic activity against hepatitis C virusSteven S Good, Adel Moussa, Xiao-Jian Zhou, et al.
Plos Neglected Tropical Diseases|January 24, 2022
AT-752, a double prodrug of a guanosine nucleotide analog, inhibits yellow fever virus in a hamster modelKai Lin, Steven S Good, Justin G Julander, et al.
Antiviral Research|March 7, 2025
Bemnifosbuvir and ruzasvir in combination exhibit potent synergistic antiviral activity in vitro while maintaining a favorable nonclinical safety profile in vivoSteven S Good, Shouqi Luo, Kai Lin, et al.
Expert Opinion on Investigational Drugs|January 24, 2024
Bemnifosbuvir (BEM, AT-527), a novel nucleotide analogue inhibitor of the hepatitis C virus NS5B polymeraseXiao-Jian Zhou, Steven S Good, Keith Pietropaolo, et al.
Antimicrobial Agents and Chemotherapy|August 23, 2021
Evaluation of AT-752, a Double Prodrug of a Guanosine Nucleotide Analog with <i>In Vitro</i> and <i>In Vivo</i> Activity against Dengue and Other FlavivirusesSteven S Good, Ashleigh Shannon, Kai Lin, et al.
Antimicrobial Agents and Chemotherapy|July 18, 2002
Preclinical and toxicology studies of 1263W94, a potent and selective inhibitor of human cytomegalovirus replicationGeorge W Koszalka, Nelson W Johnson, Steven S Good, et al.
Antimicrobial Agents and Chemotherapy|February 9, 2021
AT-527, a Double Prodrug of a Guanosine Nucleotide Analog, Is a Potent Inhibitor of SARS-CoV-2 <i>In Vitro</i> and a Promising Oral Antiviral for Treatment of COVID-19Steven S Good, Jonna Westover, Kie Hoon Jung, et al.
Antimicrobial Agents and Chemotherapy|October 2, 2019
Safety, pharmacokinetics and antiviral activity of AT-527, a novel purine nucleotide prodrug, in HCV-infected subjects with and without cirrhosisElina Berliba, Maxim Bogus, Frédéric Vanhoutte, et al.
European Journal of Drug Metabolism and Pharmacokinetics|April 23, 2015
Pharmacokinetics of IDX184, a liver-targeted oral prodrug of 2'-methylguanosine-5'-monophosphate, in the monkey and formulation optimization for human exposureXin-Ru Pan-Zhou, Benjamin A Mayes, Hassan Rashidzadeh, et al.
Pageof 2